Print this page
-
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).
Protocol: 082212Principal Investigator:
- Thomas Jang M.D (Rutgers University)
Applicable Disease Sites: Other Male Genital -
A Randomized Phase III Trial oflntravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE).
Protocol: 082303Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib
Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Protocol: 082404Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
Understanding the Role of p53 in the Development and Progression of Oligometastatic Castration-Sensitive Prostate Cancer.
Protocol: 152102Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Prostate -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Pancreas
Melanoma, Skin
Colon
Ovary
Soft Tissue
Prostate
Kidney
Breast -
Personalized Oncology Promoting Equity for Black Lives (PROPEL)
Protocol: 132309Principal Investigator:
- Anita Kinney PhD,RN (Rutgers University)
Applicable Disease Sites: Corpus Uteri
Prostate
Pancreas
Breast
Ovary
Colon